Tigecycline PCD Pharma Franchise Company
Cafoli Lifecare is a WHO-GMP certified PCD pharma franchise company offering Tigecycline — currently 1 formulation, supplied as an injection — to franchise partners, institutional suppliers and critical care distributors across India. The product is manufactured at approved facilities and offered with district-level monopoly rights.
What is Tigecycline?
Tigecycline is a broad-spectrum intravenous antibiotic and the first member of the glycylcycline class, structurally derived from minocycline. It binds the bacterial 30S ribosomal subunit and blocks protein synthesis, and because of a structural modification it evades the two commonest tetracycline resistance mechanisms — efflux pumps and ribosomal protection. This gives it activity against many multidrug-resistant Gram-positive and Gram-negative organisms. It is a prescription-only, hospital-administered reserve antibiotic. Compound and pharmacology data are available on PubChem.
Tigecycline Formulations Available with Cafoli Lifecare
Our Tigecycline range consists of 1 formulation in injection form, intended for intravenous administration in a hospital setting. Vial strength, packing and net rate are shared on enquiry.
Therapeutic Applications of Tigecycline
- Complicated intra-abdominal infections
- Complicated skin and soft tissue infections
- Community-acquired bacterial pneumonia
- Selected infections caused by multidrug-resistant organisms, where culture and sensitivity support its use
Prescribers are intensivists and critical care physicians, infectious disease specialists, surgeons and pulmonologists. Use should always follow antimicrobial stewardship policy and sensitivity reports — Tigecycline is a reserve agent, not an empirical first-line antibiotic.
Why Tigecycline is a High-Potential Molecule for Distributors
Antimicrobial resistance is the structural driver behind this molecule. As ESBL-producing and carbapenem-resistant organisms become routine findings in Indian ICU culture reports, the shortlist of agents that still work keeps narrowing — and Tigecycline remains on that shortlist. Commercially, this is an institutional rather than a retail play: demand comes from hospital pharmacies, ICUs and rate contracts, order sizes are lump-sum rather than strip-by-strip, and the value per vial is high. For a distributor already servicing hospitals, adding a reserve injectable like Tigecycline deepens an existing account rather than requiring a new field team. The trade-off is that volumes are stewardship-controlled, so this is a margin molecule, not a volume molecule.
Why Choose Cafoli Lifecare for Your Tigecycline Franchise
- Monopoly rights — one partner per district, territory protected
- WHO-GMP certified manufacturing and DCGI-approved formulations
- Promotional inputs — literature, visual aids and institutional documentation support
- 1000+ franchise partners across India
- On-time despatch, transparent net rates and dedicated order support
References
- PubChem — Tigecycline compound record, National Library of Medicine
- WHO — Antimicrobial resistance fact sheet
- PubMed — clinical literature on tigecycline
Our formulations of Tigecycline find application in many critical therapeutic areas. Its therapeutic spectrum includes, but is not limited to: